Simcere Pharmaceutical Expects FY2025 Profit Attributable to Shareholders of RMB1.3 Billion to RMB1.4 Billion

Reuters

Feb 25

<a href="https://laohu8.com/S/SMHGF">Simcere Pharmaceutical</a> Expects FY2025 Profit Attributable to Shareholders of RMB1.3 Billion to RMB1.4 Billion

Simcere Pharmaceutical Group Ltd. expects FY2025 revenue of about RMB7.7 billion to RMB7.8 billion, up roughly 16.0% to 17.6% from the restated RMB6.635 billion in FY2024. Profit attributable to equity shareholders is forecast at around RMB1.3 billion to RMB1.4 billion, an increase of about 80.1% to 93.9% versus the restated RMB722 million a year earlier, while adjusted profit attributable to equity shareholders is expected to be RMB1.25 billion to RMB1.35 billion, up about 24.1% to 34.1% from the restated RMB1.007 billion. The company attributed the improvement mainly to higher revenue from its innovative pharmaceutical business, out-licensing income, and fair value gains on its investment portfolio.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simcere Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260225-12029442), on February 25, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2614047027"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614047027\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614047027?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 17:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614047027","market":"us","top_or_hot":-1,"title":"Simcere Pharmaceutical Expects FY2025 Profit Attributable to Shareholders of RMB1.3 Billion to RMB1.4 Billion","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SMHGF\">Simcere Pharmaceutical</a> Expects FY2025 Profit Attributable to Shareholders of RMB1.3 Billion to RMB1.4 Billion\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Simcere Pharmaceutical Group Ltd. expects FY2025 revenue of about RMB7.7 billion to RMB7.8 billion, up roughly 16.0% to 17.6% from the restated RMB6.635 billion in FY2024. Profit attributable to equity shareholders is forecast at around RMB1.3 billion to RMB1.4 billion, an increase of about 80.1% to 93.9% versus the restated RMB722 million a year earlier, while adjusted profit attributable to equity shareholders is expected to be RMB1.25 billion to RMB1.35 billion, up about 24.1% to 34.1% from the restated RMB1.007 billion. The company attributed the improvement mainly to higher revenue from its innovative pharmaceutical business, out-licensing income, and fair value gains on its investment portfolio.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simcere Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260225-12029442), on February 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Simcere Pharmaceutical Expects FY2025 Profit Attributable to Shareholders of RMB1.3 Billion to RMB1.4 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSimcere Pharmaceutical Expects FY2025 Profit Attributable to Shareholders of RMB1.3 Billion to RMB1.4 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-25 17:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SMHGF\">Simcere Pharmaceutical</a> Expects FY2025 Profit Attributable to Shareholders of RMB1.3 Billion to RMB1.4 Billion\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Simcere Pharmaceutical Group Ltd. expects FY2025 revenue of about RMB7.7 billion to RMB7.8 billion, up roughly 16.0% to 17.6% from the restated RMB6.635 billion in FY2024. Profit attributable to equity shareholders is forecast at around RMB1.3 billion to RMB1.4 billion, an increase of about 80.1% to 93.9% versus the restated RMB722 million a year earlier, while adjusted profit attributable to equity shareholders is expected to be RMB1.25 billion to RMB1.35 billion, up about 24.1% to 34.1% from the restated RMB1.007 billion. The company attributed the improvement mainly to higher revenue from its innovative pharmaceutical business, out-licensing income, and fair value gains on its investment portfolio.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simcere Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260225-12029442), on February 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02096","symbol_name":"先声药业","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL3NdFXV:1","article_id":"2614047027","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614047027","pubTimestamp":1772011017,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Simcere Pharmaceutical Group Ltd. expects FY2025 revenue of about RMB7.7 billion to RMB7.8 billion, up roughly 16.0% to 17.6% from the restated RMB6.635 billion in FY2024. Profit attributable to equity shareholders is forecast at around RMB1.3 billion to RMB1.4 billion, an increase of about 80.1% to 93.9% versus the restated RMB722 million a year earlier, while adjusted profit attributable to equity shareholders is expected to be RMB1.25 billion to RMB1.35 billion, up about 24.1% to 34.1% from the restated RMB1.007 billion. The company attributed the improvement mainly to higher revenue from its innovative pharmaceutical business, out-licensing income, and fair value gains on its investment portfolio.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or l","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02096":"先声药业","BK1583":"高瓴概念","BK1191":"制药"},"translate_title":"先声药业预计2025财年股东应占利润人民币13亿元至人民币14亿元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02096":0.9},"content_text":"Simcere Pharmaceutical Expects FY2025 Profit Attributable to Shareholders of RMB1.3 Billion to RMB1.4 Billion\n    \n\n        Simcere Pharmaceutical Group Ltd. expects FY2025 revenue of about RMB7.7 billion to RMB7.8 billion, up roughly 16.0% to 17.6% from the restated RMB6.635 billion in FY2024. Profit attributable to equity shareholders is forecast at around RMB1.3 billion to RMB1.4 billion, an increase of about 80.1% to 93.9% versus the restated RMB722 million a year earlier, while adjusted profit attributable to equity shareholders is expected to be RMB1.25 billion to RMB1.35 billion, up about 24.1% to 34.1% from the restated RMB1.007 billion. The company attributed the improvement mainly to higher revenue from its innovative pharmaceutical business, out-licensing income, and fair value gains on its investment portfolio.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simcere Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260225-12029442), on February 25, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}